Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Aug 6, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Aug 6, 2025, with Reg FD and financial updates.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and has its principal executive offices in Toronto.
Why It Matters
This filing provides updates on Aptose Biosciences' regulatory and financial disclosures, which are important for investors to understand the company's current status and compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating standard disclosures rather than a significant event.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- Toronto (location) — Business address city
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 6, 2025.
What is Aptose Biosciences Inc.'s state of incorporation?
Aptose Biosciences Inc. is incorporated in Canada.
What were some of Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
Where are Aptose Biosciences Inc.'s principal executive offices located?
Aptose Biosciences Inc.'s principal executive offices are located at 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, A6, M5K 1E6.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Aptose Biosciences Inc. (APTOF).